Lack of evidence for xenotropic murine leukemia virus-related virus(XMRV) in German prostate cancer patients

doi:10.1186/1742-4690-6-92

Retrovirology

Volume 6

Viewing options:

Abstract
Full text
PDF (1.9MB)

Associated material:

Related literature:

Articles citing this article
on BioMed Central
on Google Scholar
on ISI Web of Science
on PubMed Central
Other articles by authors
on Google Scholar

Hohn O
Krause H
Barbarotto P
Niederstadt L
Beimforde N
Denner J
Miller K
Kurth R
Bannert N

on PubMed

Hohn O
Krause H
Barbarotto P
Niederstadt L
Beimforde N
Denner J
Miller K
Kurth R
Bannert N
Related articles/pages
on Google

on Google Scholar

on PubMed

Tools:

Post to:

Research

Lack of evidence for xenotropic murine leukemia virus-related virus(XMRV) in German prostate cancer patients

Oliver Hohn¹^* , Hans Krause²^* , Pia Barbarotto¹ , Lars Niederstadt¹ , Nadine Beimforde¹^,3 , Joachim Denner⁴ , Kurt Miller² , Reinhard Kurth¹ and Norbert Bannert¹

¹Robert Koch-Institute, Centre for Biological Safety 4, Nordufer 20, 13353 Berlin, Germany

²Charité - Universitätsmedizin Berlin, Urologische Klinik, Schumannstraße 20/21, 10117 Berlin, Germany

³Charité - Universitätsmedizin Berlin, Hindenburgdamm 30, 12203 Berlin

⁴Robert Koch-Institute, Retrovirus induced immunosuppression (P13), Nordufer 20, 13353 Berlin, Germany

author email corresponding author email* Contributed equally

Retrovirology 2009, 6:92doi:10.1186/1742-4690-6-92


Published:	16 October 2009

Abstract

Background

A novel gammaretrovirus named xenotropic murine leukemia virus-related virus (XMRV) has been recently identified and found to have a prevalence of 40% in prostate tumor samples from American patients carrying a homozygous R462Q mutation in the RNaseL gene. This mutation impairs the function of the innate antiviral type I interferon pathway and is a known susceptibility factor for prostate cancer. Here, we attempt to measure the prevalence of XMRV in prostate cancer cases in Germany and determine whether an analogous association with the R462Q polymorphism exists.

Results

589 prostate tumor samples were genotyped by real-time PCR with regard to the RNaseL mutation. DNA and RNA samples from these patients were screened for the presence of XMRV-specific gag sequences using a highly sensitive nested PCR and RT-PCR approach. Furthermore, 146 sera samples from prostate tumor patients were tested for XMRV Gag and Env antibodies using a newly developed ELISA assay. In agreement with earlier data, 12.9% (76 samples) were shown to be of the QQ genotype. However, XMRV specific sequences were detected at neither the DNA nor the RNA level. Consistent with this result, none of the sera analyzed from prostate cancer patients contained XMRV-specific antibodies.

Conclusion

Our results indicate a much lower prevalence (or even complete absence) of XMRV in prostate tumor patients in Germany. One possible reason for this could be a geographically restricted incidence of XMRV infections.